Similar companies
| Company | Business Outlook | |
|---|---|---|
 |
AmgenAMGN |
77 0% |
 |
Gilead SciencesGILD |
59 1.7% |
 |
Catalyst PharmaceuticalsCPRX |
100 0% |
 |
Inovio PharmaceuticalsINO |
23 0% |
 |
Anavex Life SciencesAVXL |
0 0% |
Month over Month
Employee view on business outlook (0 - 100)
| Nov 2024 | 13 | |
| Oct 2024 | 15 | |
| Sep 2024 | 15 | |
| Aug 2024 | 21 |
How do employees feel about the future at 23andMe?
According to employees, the Business Outlook at 23andMe is highly negative. This is reflected in the average rating of 16 out of 100, which is considered very low. But this rating (aggregated from the top review sites in the US) is up by 23.1% since the previous month.
Analyzing Business Outlook, how is 23andMe performing compared to its industry peers?
23andMe underperforms its industry peers when it comes to Business Outlook, ranking in the 16th percentile.
How has the business outlook at 23andMe changed over the last couple of months
In recent months, 23andMe's employees have reported a shift towards a more positive business outlook, indicating improved company morale and potentially leading to increased market competitiveness and enhanced company performance.
Why is it important to track the business outlook at 23andMe?
Tracking a company's business outlook is important as a positive outlook can indicate future growth and profitability and attract new talent, while a negative outlook can discourage talent and imply demotivated employees. Additionally, data shows that companies with a high business outlook tend to perform better on the stock market compared to those with a lower business outlook.
Sign up and get more insights on the business outlook at 23andMe.
